Pioglitazone Alters Ace/Ace 2 Balance to Favour Ace2 Independently Of Glycaemia Levels in Diabetic Rat Heart.

• DOI: 10.1691/ph.2023.3570
• Publication Date: 2023-08-01
• Authors: Eva Kráľová; Katarína Hadová; Aneta Čináková; Peter Křenek; Ján Klimas
• Keywords: Pioglitazone; Diabetic Cardiomyopathy; Angiotensin-converting enzyme 2

The activation of the renin-angiotensin system (RAS) contributes to pathogenesis cardiac damage during diabetes. In present study, we investigated role pioglitazone, dapagliflozin and their combination on RAS components in streptozotocin-induced diabetic cardiomyopathy Wistar rats. Blood glucose, serum lipids, ACE (angiotensin-converting enzyme), ACE2 levels were determined. mRNA Myh6 (myosins heavy chain), Myh7, Ace, Ace2, Nppa, Nppb (natriuretic peptide A, B) Ppars (peroxisome proliferator activating receptors) genes heart determined by real-time PCR (polymerase chain reaction). Protein expression was assessed western blotting. After six weeks pioglitazone suppressed Ace protein (p<0.05) modified Ace/Ace2 ratio tissue Pioglitazone significantly decreased lipids but did not influence blood glucose animals. Dapagliflozin had a significant glucose-lowering action however, it no impact ratio. both compounds markedly improved as well Myh6/Myh7 further Ace2 balance compared monotherapy. We found that improves Ace/ rats suggesting potential cardioprotective effect. This effect is independent its antidiabetic metabolic effects.